Exacerbation of Previously Undiagnosed Bird Fancier's Lung by Pembrolizumab Therapy

Research output: Contribution to journalArticle

Abstract

Immune checkpoint inhibitors have revolutionized cancer therapy. As the use of checkpoint inhibitors becomes widespread, the early recognition and treatment of their unique spectrum of adverse effects, called immune-related adverse events, become critical. Perhaps the most significant of these is the pulmonary toxicity currently described as “pneumonitis.” However, little is known about the effects of immune checkpoint inhibitors on preexisting interstitial lung disease. We present a case of subclinical hypersensitivity pneumonitis that was exacerbated by pembrolizumab, a programmed cell death-1 inhibitor. This case illustrates a new immune-related adverse event and suggests that exacerbation of preexisting interstitial lung disease is a potential pulmonary toxicity from immune checkpoint inhibitor therapy.

Original languageEnglish (US)
Pages (from-to)e79-e82
JournalChest
Volume155
Issue number4
DOIs
StatePublished - Apr 1 2019

Fingerprint

Bird Fancier's Lung
Interstitial Lung Diseases
Extrinsic Allergic Alveolitis
Lung
Pneumonia
Cell Death
Therapeutics
Neoplasms
pembrolizumab

Keywords

  • Bird fancier‘s lung
  • checkpoint inhibitors
  • hypersensitivity pneumonitis
  • immune-related adverse event
  • pembrolizumab pneumonitis

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Exacerbation of Previously Undiagnosed Bird Fancier's Lung by Pembrolizumab Therapy. / Vu, Ann; Vassallo, Robert; Ryu, Jay H.

In: Chest, Vol. 155, No. 4, 01.04.2019, p. e79-e82.

Research output: Contribution to journalArticle

@article{ce9d940c4c5941fd96bfc2656a8ab2dd,
title = "Exacerbation of Previously Undiagnosed Bird Fancier's Lung by Pembrolizumab Therapy",
abstract = "Immune checkpoint inhibitors have revolutionized cancer therapy. As the use of checkpoint inhibitors becomes widespread, the early recognition and treatment of their unique spectrum of adverse effects, called immune-related adverse events, become critical. Perhaps the most significant of these is the pulmonary toxicity currently described as “pneumonitis.” However, little is known about the effects of immune checkpoint inhibitors on preexisting interstitial lung disease. We present a case of subclinical hypersensitivity pneumonitis that was exacerbated by pembrolizumab, a programmed cell death-1 inhibitor. This case illustrates a new immune-related adverse event and suggests that exacerbation of preexisting interstitial lung disease is a potential pulmonary toxicity from immune checkpoint inhibitor therapy.",
keywords = "Bird fancier‘s lung, checkpoint inhibitors, hypersensitivity pneumonitis, immune-related adverse event, pembrolizumab pneumonitis",
author = "Ann Vu and Robert Vassallo and Ryu, {Jay H}",
year = "2019",
month = "4",
day = "1",
doi = "10.1016/j.chest.2018.12.002",
language = "English (US)",
volume = "155",
pages = "e79--e82",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "4",

}

TY - JOUR

T1 - Exacerbation of Previously Undiagnosed Bird Fancier's Lung by Pembrolizumab Therapy

AU - Vu, Ann

AU - Vassallo, Robert

AU - Ryu, Jay H

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Immune checkpoint inhibitors have revolutionized cancer therapy. As the use of checkpoint inhibitors becomes widespread, the early recognition and treatment of their unique spectrum of adverse effects, called immune-related adverse events, become critical. Perhaps the most significant of these is the pulmonary toxicity currently described as “pneumonitis.” However, little is known about the effects of immune checkpoint inhibitors on preexisting interstitial lung disease. We present a case of subclinical hypersensitivity pneumonitis that was exacerbated by pembrolizumab, a programmed cell death-1 inhibitor. This case illustrates a new immune-related adverse event and suggests that exacerbation of preexisting interstitial lung disease is a potential pulmonary toxicity from immune checkpoint inhibitor therapy.

AB - Immune checkpoint inhibitors have revolutionized cancer therapy. As the use of checkpoint inhibitors becomes widespread, the early recognition and treatment of their unique spectrum of adverse effects, called immune-related adverse events, become critical. Perhaps the most significant of these is the pulmonary toxicity currently described as “pneumonitis.” However, little is known about the effects of immune checkpoint inhibitors on preexisting interstitial lung disease. We present a case of subclinical hypersensitivity pneumonitis that was exacerbated by pembrolizumab, a programmed cell death-1 inhibitor. This case illustrates a new immune-related adverse event and suggests that exacerbation of preexisting interstitial lung disease is a potential pulmonary toxicity from immune checkpoint inhibitor therapy.

KW - Bird fancier‘s lung

KW - checkpoint inhibitors

KW - hypersensitivity pneumonitis

KW - immune-related adverse event

KW - pembrolizumab pneumonitis

UR - http://www.scopus.com/inward/record.url?scp=85063334033&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063334033&partnerID=8YFLogxK

U2 - 10.1016/j.chest.2018.12.002

DO - 10.1016/j.chest.2018.12.002

M3 - Article

C2 - 30955583

AN - SCOPUS:85063334033

VL - 155

SP - e79-e82

JO - Chest

JF - Chest

SN - 0012-3692

IS - 4

ER -